Want to see IRTC full AI Analyst Report?
IRTC Stock Chart & Stats
$109.20
$1.53(1.42%)
At close: 4:00 PM EDT
$109.20
$1.53(1.42%)
Day’s Range― - ―
52-Week Range$100.85 - $212.00
Previous CloseN/A
Volume317.85K
Average Volume (3M)551.13K
Market Cap
$3.85B
Enterprise Value$4.02K
Total Cash (Recent Filing)$549.62M
Total Debt (Recent Filing)$729.29M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 06, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding32,862,408
10 Day Avg. Volume441,722
30 Day Avg. Volume551,129
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$174.88Price Target Upside60.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$881.10M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth & Upward GuidanceConsistent high-teens to mid-20s revenue growth and a raised full-year guide indicate durable demand for Zio monitoring. Growing prescription volume and enterprise uptake support recurring per-episode revenue, improving revenue visibility and enabling investment in scale and product expansion over the next several quarters.
High And Improving Gross MarginsSustained ~70% gross margin reflects strong unit economics from device/software blend and scale benefits. Margin expansion from automation and clinical efficiencies suggests durable operating leverage that can support profitability as revenue scales and reduce incremental cost per monitored episode.
Improving Cash Generation And Large Cash BalanceTransition to positive operating cash flow and a substantial cash balance provide funding optionality for R&D, commercialization, and legal contingencies. Positive free cash flow in TTM signals business model moving toward self-funding, reducing reliance on external financing over the medium term.
Bears Say
Elevated Balance-Sheet LeverageA debt-heavy capital structure materially constrains financial flexibility and raises refinancing and interest-rate sensitivity. High leverage increases execution risk for expansion and makes the company more vulnerable to cash-flow volatility or slower adoption, lengthening time to durable profitability.
Persisting GAAP Net LossesAlthough losses have narrowed, ongoing GAAP deficits limit retained earnings accumulation and elongate the path to sustained EPS positive results. Continued operating losses could pressure capital raises or require higher earnings conversion to justify reinvestment and cover fixed costs as the business scales.
Regulatory And Legal OverhangsOpen FDA and DOJ matters create uncertain timing for final agency actions and potential remediation costs or product constraints. Regulatory scrutiny and investigations can affect reimbursement, product approvals, and customer confidence, posing sustained execution and cost risks until fully resolved.
Irhythm Technologies News
IRTC FAQ
What was Irhythm Technologies’s price range in the past 12 months?
Irhythm Technologies lowest stock price was $100.84 and its highest was $212.00 in the past 12 months.
What is Irhythm Technologies’s market cap?
Irhythm Technologies’s market cap is $3.85B.
When is Irhythm Technologies’s upcoming earnings report date?
Irhythm Technologies’s upcoming earnings report date is Aug 06, 2026 which is in 3 days.
How were Irhythm Technologies’s earnings last quarter?
Irhythm Technologies released its earnings results on Apr 30, 2026. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.659 by $0.229.
Is Irhythm Technologies overvalued?
According to Wall Street analysts Irhythm Technologies’s price is currently Undervalued.
Does Irhythm Technologies pay dividends?
Irhythm Technologies does not currently pay dividends.
What is Irhythm Technologies’s EPS estimate?
Irhythm Technologies’s EPS estimate is -0.04.
How many shares outstanding does Irhythm Technologies have?
Irhythm Technologies has 32,862,408 shares outstanding.
What happened to Irhythm Technologies’s price movement after its last earnings report?
Irhythm Technologies reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.659. Following the earnings report the stock price went down -6.473%.
Which hedge fund is a major shareholder of Irhythm Technologies?
Currently, no hedge funds are holding shares in IRTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Irhythm Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$174.88 (60.14% Upside)
$174.88 (60.14% Upside)
Blogger Sentiment
Bullish
IRTC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $678.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.67%
Trailing 12-Months
Company Description
Irhythm Technologies
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
IRTC Company Deck
IRTC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was constructive and predominantly positive: the company delivered strong top-line growth (≈26% YoY), meaningful margin expansion (880 bps adjusted EBITDA improvement and +210 bps gross margin), raised full‑year revenue and EBITDA guidance, and showed progress on product, AI, clinical evidence, and international commercialization. Offsetting items include continued GAAP/adjusted net losses (though improved), seasonally negative Q1 free cash flow, elevated operating and litigation-related costs, and outstanding regulatory and legal uncertainties (FDA warning letter, DOJ CID) plus potential coverage ambiguity from proposed LCD language. On balance, the operational and commercial positives materially outweigh the remaining execution and regulatory risks.View all IRTC earnings summariesIRTC Stock 12 Month Forecast
Average Price Target
$174.88
▲(60.14% Upside)
Technical Analysis
Ownership Overview
1.84% Insiders
31.24% Mutual Funds
2.86% Other Institutional Investors
48.59% Public Companies and
Individual Investors